AUROPHARMA logo

Aurobindo Pharma Limited Stock Price

NSEI:AUROPHARMA Community·₹656.5b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 27 Fair Values set on narratives written by author

AUROPHARMA Share Price Performance

₹1,136.80
-352.45 (-23.67%)
34.1% undervalued intrinsic discount
₹1,723.98
Fair Value
₹1,136.80
-352.45 (-23.67%)
41.1% undervalued intrinsic discount
₹1,930.00
Fair Value
Price ₹1,136.80
AnalystHighTarget ₹1,930.00
AnalystConsensusTarget ₹1,293.39
AnalystLowTarget ₹730.00

AUROPHARMA Community Narratives

AnalystHighTarget·
Fair Value ₹1.72k 34.1% undervalued intrinsic discount

Complex Generics And Biosimilars Will Fuel Secular Demand

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value ₹1.29k 12.1% undervalued intrinsic discount

Biosimilars Expansion And EU Approvals Will Unlock Global Markets

0users have liked this narrative
0users have commented on this narrative
20users have followed this narrative
AnalystLowTarget·
Fair Value ₹862.8 31.8% overvalued intrinsic discount

US And European Pressures Will Drive Margin Compression

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent AUROPHARMA News & Updates

Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?

Sep 26
Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?

We Discuss Whether Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Is Due For A Pay Rise

Sep 04
We Discuss Whether Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Is Due For A Pay Rise

Estimating The Fair Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Aug 27
Estimating The Fair Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Aurobindo Pharma Limited Key Details

₹320.2b

Revenue

₹131.9b

Cost of Revenue

₹188.3b

Gross Profit

₹154.4b

Other Expenses

₹33.9b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 14, 2025
Earnings per share (EPS)
58.39
Gross Margin
58.80%
Net Profit Margin
10.59%
Debt/Equity Ratio
25.3%

Aurobindo Pharma Limited Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet and fair value.

1 Risk
3 Rewards

About AUROPHARMA

Founded
1986
Employees
27707
CEO
Kambam Reddy
WebsiteView website
www.aurobindo.com

Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and API space for sterile and non-sterile penicillin’s, cephalosporins, penems, and non-beta lactams. The company has operations in India, the United States, Europe, Puerto Rico, and internationally. The company was incorporated in 1986 and is headquartered in Hyderabad, India.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

Indian Market Performance

  • 7 Days: 0.9%
  • 3 Months: 0.1%
  • 1 Year: -4.1%
  • Year to Date: 1.6%
In the last week, the market has stayed flat, however the Information Technology sector stood out, gaining 3.8%. The past year hasn't been profitable, with the market dropping 4.1%. As for the next few years, earnings are expected to grow by 16% per annum. Market details ›